Transglutaminases: the missing link in nephrogenic systemic fibrosis.

Area of Science:

• Nephrology
• Dermatology
• Biochemistry

Background:

• Nephrogenic systemic fibrosis (NSF), or nephrogenic fibrosing dermopathy (NFD), is a debilitating condition affecting patients with renal failure following exposure to gadolinium-based contrast agents.
• NSF is characterized by widespread fibrosis affecting the skin, subcutaneous tissues, and internal organs such as the heart, liver, lungs, and muscles.
• The precise mechanism linking gadolinium exposure to fibrotic processes in NSF remains unclear.

Purpose of the Study:

• To investigate the potential role of transglutaminase enzymes in the pathogenesis of NSF.
• To test the hypothesis that the upregulation of transglutaminases contributes to the fibrotic changes observed in NSF patients.

Main Methods:

• Immunohistochemical analysis was performed on five archived skin biopsies from patients diagnosed with NSF.
• Antibodies targeting transglutaminase-2, factor XIIIa, transglutaminase isopeptide, and the histiocyte marker CD68 were utilized.

Main Results:

• Dermal fibroblasts and histiocytes in NSF skin biopsies demonstrated expression of transglutaminase-2, CD68, factor XIIIa, and transglutaminase isopeptide.
• These findings indicate an increased expression and/or activation of transglutaminases within the affected tissues of NSF patients.

Conclusions:

• The study provides evidence supporting the involvement of transglutaminases in the fibrotic process of NSF.
• Further research into transglutaminase inhibitors is recommended for the potential treatment and prevention of NSF.